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ABSTRACT
An In Vitro And In Vivo Evaluation of The Anticancer Potential Of Resveratrol And
Pterostilbene Against Hpv-E6 Positive Cancers.
By
Kaushiki Chatterjee
Advisor: Dr. Jimmie E. Fata

Cervical cancer remains as one of the most prevalent cancers effecting women globally. Lack of
awareness and affordable prophylactic and therapeutic options in developing countries drive the
need for alternative low-cost approaches. Dietary polyphenols have gained increased attention as
possible anti-cancer agents. Our study aims to investigate whether two natural structural analogs,
resveratrol and pterostilbene, exhibit anti-HPV (Human papillomavirus) activity in cervical
cancer. To determine the efficacy of these polyphenols, extensive in vitro and in vivo analyses
were carried out. For the in vitro studies we utilized human HeLa cells (HPV18 positive) and
murine TC1 cells (HPV 16 oncogene positive). Both these plant polyphenols show efficacy
against these cell lines with low IC50 values in the µM range. In HeLa cells we looked at E6
protein expression, downstream p53 expression and activation of caspase 3 as a means to
understand the mechanism of action. Both resveratrol and pterostilbene showed efficacy against
HeLa by eliciting S-phase growth arrest, decreasing mitotic activity and impairing it’s
clonogenicity. These findings were significant, with pterostilbene often being more effective
than resveratrol. Results point to a possible mechanism in HPV18 which involves the
downregulation of HPV E6 oncogene, stabilization of functional p53 and activation of the
apoptotic pathway. Further in vitro analysis on TC1 cells confirmed the cytotoxic potential of
both resveratrol and pterostilbene and their ability to downregulate E6 oncoprotein. Our in vivo
studies on TC1 tumors established in mice elucidated that both compounds substantially decrease
iv

tumor load with E6 and VEGF protein downregulation. Intriguingly, the tumor reduction induced
by pterostilbene is caused by apoptosis via activation of caspase 3, whereas, the efficacy of
resveratrol is a due to growth arrest indicated by suppressed PCNA expression. Thus, our results
show the antineoplastic potential of resveratrol and pterostilbene against both HPV18 and
HPV16 cervical cancers. These findings show their robust anti-tumor potential and warrants the
need for future clinical trials utilizing these food- derived compounds as nontoxic therapeutic
agents.

v

Acknowledgements

Firstly, I want to convey my deepest gratitude to my mentor Dr. Jimmie E. Fata for his guidance
and support throughout my dissertation work. He has been a great support both inside and
outside the lab. I am fortunate to be under the tutelage of such a caring person. He encouraged
independent scientific thinking and taught be valuable life lessons.
I thank my committee members Dr. Greg Phillips, Dr. Edward Kennelly, Dr. Abdeslem Elidrissi
and Dr. Krishnaswami Raja (also collaborator) for their scientific inputs and constructive ideas
and criticisms. I thank Dr. Shawon Debnath for agreeing to serve on my committee on such short
notice. I would also like to thank Dr. Probal Banerjee and Dr. Nan Lo Yang for collaborating
with us.
I am deeply grateful to all members of the Fata lab past and present who have supported and
encouraged me during my PhD. I would specially like to thank Dina Alsharif, Jonathan
VanManen, Christina Mazza, Palwasha Syer and Mohamed Alsharif who have worked with me
and shown true dedication to the project. I would like to thank my friends Samantha, Hassan
Harini, Dibash and Jeannette for being such good friends and encouraging me.
My gratitude to all my teachers who have taught me and inspired me to pursue scientific
research. I would like to thank the Biology department at College of Staten Island and the
Graduate Center for their constant advisement and support. I thank the Staten Island University
Hospital for their financial support.
I would like to thank Dr. Sumit Mukherjee my collaborator and husband for his constant support
and scientific inputs. I thank my sister Sreyashi and brother in law Prasenjeet for their
encouragement and support. I thank my grandmother for encouraging me to pursue my dreams. I
vi

thank my friends Anushree and Sudeshna, who were always pushing me forward. I thank all my
friends and colleagues at CUNY for a good collaborative work environment.
Lastly, I thank my parents Dr. Jayanta Chatterjee and Mrs. Sudeshna Chatterjee for being my
inspiration and pillars of support. Thank you for never losing faith in me and for always
encouraging me to follow my heart.

vii

Table of contents

Abstract………………………………………………………………………………….

iv

Acknowledgements………………………………………………………………………

vi

Table of Contents………………………………………………………………………...

viii

List of figures…………………………………………………………………………….

x

List of tables……………………………………………………………………………...

xi

Chapter 1: Introduction………………………………………………………………..

1

1.1 Cervical cancer; Need for an alternative therapy…………………………………….

2

1.2 Natural compounds and cervical cancer……………………………………………..

3

1.3 Resveratrol and Pterostilbene: A class of bioactive polyphenols……………………

4

1.4 Role of high risk E6 in pathogenesis of Cervical cancer…………………………….

8

1.5 Scope of Work……………………………………………………………………….

10

Chapter 2: Resveratrol and Pterostilbene Exhibit Anticancer Properties Involving
the

Downregulation

of

HPV

Oncoprotein

E6

in

Cervical

Cancer

11

Cells……………..........................................................................................................
2.1 Abstract………………………………………………………………………………

12

2.2 Materials and Methods ………………………………………………………………

13

2.3. Results……………………………………………………………………………….

18

2.3.1. Pterostilbene Is More Potent in Eliminating HPV+ HeLa Cells Compared to

18

Resveratrol……………………………………………………………………………….
2.3.2 Inhibition of Cell Migration of HeLa Cells Treated with Pterostilbene and

20

Resveratrol……………………………………………………………………………….
2.3.3 Cell Cycle Arrest at S-Phase in HeLa Cells Treated with Low Concentrations of

22

Resveratrol and Pterostilbene …………………………………………………………...
2.3.4 Downregulation of Viral Oncoprotein E6 and Upregulation of Active-Caspase-3 in

25

HeLa Cells Treated with Pterostilbene and Resveratrol ……………………………..
2.3.5. Upregulation of Tumor Suppressor Protein p53 in HeLa Cells Treated with

27

Pterostilbene and Resveratrol …………………………………………………………...
2.4. Discussion…………………………………………………………………………..

viii

30

Chapter 3: Resveratrol and Pterostilbene Inhibit E6 positive tumor growth in

35

vivo……………………………………………………………………………………….
3.1. Abstract……………………………………………………………………………...

36

3.2. Materials and Methods ……………………………………………………………...

37

3.3. Results……………………………………………………………………………….

40

3.3.1 Resveratrol and Pterostilbene are cytotoxic to TC1 cells………………………….

40

3.3.2 E6 oncoprotein gets downregulated by resveratrol and pterostilbene in vitro…….

42

3.3.3 Reduction of tumor size in mouse model by resveratrol and pterostilbene……….

44

3.3.4 Reduction of E6 oncoprotein level in vivo by resveratrol and pterostilbene………

46

3.3.5 Downregulation of PCNA protein in vivo by resveratrol and upregulation of

48

cleaved caspase 3 by pterostilbene………………………………………………………
3.3.6 Downregulation of VEGF protein in vivo by resveratrol and pterostilbene………

51

3.4 Discussion……………………………………………………………………………

53

Chapter 4: Conclusion and future directions…………………………………………

60

4.1 Concluding Remarks…………………………………………………………………

61

4.2 Future Directions…………………………………………………………………….

64

Bibliography………………………………………………………………………………. 65
Publications

74

ix

List of Illustrations
Illustration 1. Structure of resveratrol and pterostilbene……………………………

5

Illustration 2. Majors targets of E6 and their cellular consequences……………….. 8
Illustration 3. Hallmarks of cancer being targeted by E6……………………………

63

List of Figures
Figure 1. Pterostilbene is more potent in eliminating HeLa cervical cancer cells as
compared to resveratrol………………………………………………………………... 19
Figure 2. Resveratrol and pterostilbene inhibit cell migration……………………… 21
Figure 3. S-phase arrest in HeLa cells treated with low concentrations of

23

resveratrol and pterostilbene…………………………………………………………..
Figure 4. Downregulation of viral oncoprotein E6 and upregulation of active-

26

caspase-3 in HeLa cells treated with resveratrol or pterostilbene…………………...
Figure 5. Upregulation of the tumor suppressor protein p53 in HeLa cells treated

28

with resveratrol and pterostilbene……………………………………………………..
Figure 6. Resveratrol and pterostilbene are cytotoxic to TC1 cells…………………. 41
Figure 7. Viral oncoprotein E6 gets downregulated in TC1 cells treated with

43

resveratrol or pterostilbene…………………………………………………………….
Figure 8. Inhibition of tumor growth in E6+ tumor bearing mouse………………...

45

Figure 9. E6 expression is reduced in mouse tumors…………………………………

47

Figure 10. Upregulation of activated caspase 3 in mouse tumors…………………… 49
Figure 11. Downregulation of PCNA expression in mouse tumors………………….

50

Figure 12. Downregulation of VEGF expression in mouse tumors………………….

52

x

Figure 13. E7 expression in TC1 cells…………………………………………………. 56

List of Tables

Table 1: Biological activity of resveratrol and pterostilbene on cervical cancer…..

6

Table 2: Overview of clinical trials of resveratrol…………………………………

7

Table 3. Table showing the percentage of cells in each phase of the cell cycle (% ±
S.E.M.) after treatment with different concentrations of resveratrol (Res) and
25
pterostilbene (Pte). …………………………………………………………………….

xi

CHAPTER 1
INTRODUCTION

1

1.1 Cervical cancer; Need for an alternative therapy
Cervical cancer is one of the most prevalent cancers affecting women worldwide. It is the second
most common cancer in developing countries and 11th in developed countries. These regional
differences are often attributed to the lack of Pap smears, a preventative procedure often absent
in underdeveloped areas [1,2]. It is widely accepted that the etiological factor that causes cervical
cancer is chronic infection of the human papilloma virus (HPV), which is considered the most
common sexually transmitted infection [3]. Every year about 500,000 women acquire the disease
and 75% are from the developing countries [4]. Moreover, recent evidence indicates that HPV
infection is on the rise in men, leading to higher incidences of penile and oropharyngeal cancers
[5]. HPVs can be clinically classified as “low-risk” (LR-HPV) or “high-risk” (HR-HPV)
depending on the relative tendency of the HPV lesions to transform into malignancy. HPV 16
and HPV 18 are the two most important cancer-causing, high-risk HPV [6]. HPV progression to
cancer is dependent on prolonged infection by these high-risk HPV viruses. The progression of
HPV lesions to a neoplastic stage is dependent on several co-factors. Currently there are a few
standard treatment methods for cervical cancer including surgery, radiation and chemotherapy
[7]. These treatment methods have several side effects including urinary dysfunction and sexual
dysfunction [8,9]. Studies have also shown that these treatment therapies have a negative impact
on the quality of life of survivors [10,11]. Although there are approved HPV vaccines and drugs
available, a problem is the affordability of these drugs in low income areas [12]. Two such
vaccines are Cervarix® and Gardasil® [13], which renders prophylactic actions against cervical
lesions associated with the most common oncogenic HPV types, 16/18, but effective therapeutic
measures for post-infection lesions are currently not available. The major concern for the
common chemotherapeutic medicines like cisplatin and paclitaxel are their adverse side effects
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[14,15]. Even after surviving cancer after chemotherapy there may be severe long term effects
including ototoxicity, nephrotoxicity, neurotoxicity and even secondary malignancies [16].
Targeted therapies using antibodies are used to treat metastatic and recurrent cervical cancer [7].
The detrimental side effects of antiangiogenic targeted drugs such as Avastin steer the need for
an alternative treatment[17].
1.2 Natural compounds and cervical cancer
Carcinogenesis is a multi-step process from initiation to progression. Natural products derived
from plant sources have been known to have therapeutic potential since ancient times
[18].Natural compounds have been known to have several anticancer properties and are able to
target several key factors essential for cancerous progression [19]. Phytochemicals like
polyphenols, carotenoids and alkaloids have shown anti-tumor potential in different types of
cancers. Of the varied groups of natural products, polyphenols have gained increased importance
in cervical cancer since they have displayed potent antitumor properties in a number of cancers
by targeting several pathways that are involved in cancer progression [20,21]. Several studies
have shown polyphenols to be highly bioactive in attenuating cervical cancer progression
[19,22]. The most studied polyphenols in cervical cancer are curcumin found in turmeric
rhizome and epicatechin gallate found in green tea. Other polyphenols that induce apoptosis and
inhibit tumor progression are resveratrol, luteolin, quercetin, fisetin etc. [19]. Efforts have been
made to find natural product combinations that have increased efficacy both in vitro and in vivo
[21]. The development of natural chemoprotective drugs that effectively target HPV infection
could drastically reduce the incidence and progression of cervical cancer worldwide if they are
not cost prohibitive and have few side effects.

3

1.3 Resveratrol and Pterostilbene: A class of bioactive polyphenols
The current study uses cervical cancer cells to compare the tumor-inhibitory effects and
mechanism of action of two such polyphenols, resveratrol and pterostilbene. Both resveratrol and
pterostilbene have been found by HPLC to be the major constituents of ancient ayurvedic
medicine 'Darakchasava' [23]. Both these compounds are stilbenes, which are a class of natural
polyphenolic compounds that have been studied for their anticarcinogenic activities.
Resveratrol (3,4,5-trihydroxy-trans-stilbene), a natural polyphenol (Illustration1A), was first
isolated and characterized in 1940 by Takaoka from the roots of Veratrum grandiflorum [24].
Later it has been isolated from several plant species including grapes, red wine, purple grape
juice, peanuts, berries, and some medicinal plants [25]. Resveratrol is a widely studied stilbene
compound having very low toxicity in the human system, and it is also known to modulate
several pathways that are directly linked to cancer progression [26]. Resveratrol is a debated
compound amongst scientists and often termed as a pan assay interfering compound
[27].However scientists continue to find various beneficial properties of resveratrol in cancer and
other diseases [28,29]. Previous studies by our team have used resveratrol in combination with
bioactive polyphenols curcumin and epicatechin gallate. There was evidence of superior efficacy
and synergism in both cervical cancer and glioblastoma [30,31]. We wanted to explore the
potential of resveratrol alone on cervical cancer and to understand the underlying mechanism of
action.

Both in vitro and in vivo cancer studies have shown resveratrol to inhibit cell

proliferation and angiogenesis along with inducing pro-apoptotic signals [32]. Resveratrol has
been widely studied on cervical cancer and has shown promising results (Table 1). Multiple
clinical trials using resveratrol have shown promising results (Table 2). In spite of several in
vitro studies there is a dearth of in vivo or clinical studies of resveratrol on cervical cancer. The
4

potential problem of using resveratrol as a chemoprotective agent is that it has low systemic
bioavailability, which might lower its efficacy in the human system [33]. In order to overcome
this, several efforts are being made to develop resveratrol derivatives with higher systemic
bioavailability [34]. We set out to look for a better alternative to resveratrol.

Illustration 1. Structure of resveratrol and pterostilbene
Pterostilbene (trans-3,5-dimethoxy-4-hydroxystilbene) is a naturally derived dimethylether
analogue of resveratrol (Illustration 1B). Pterostilbene is believed to be produced in plants as a
defense mechanism against some external microbial or fungal infection and is therefore
considered a phytoalexin [35]. It has been isolated from grapevine leaves and blueberries [36].
Recently, pterostilbene has gained much attention as a possible anticancer agent, showing no
toxicity in humans up to a dose of 250 mg/day [36,37]. Although the chemical structure of
pterostilbene is closely related to resveratrol, the substitution of the hydroxyl group with a
methoxy group in pterostilbene is believed to make the molecule more stable as well as increase
its capacity to enter cells [38]. In addition, clinical studies have shown that the half-life and oral
bioavailability of pterostilbene are significantly greater than those of resveratrol [37]. Studies on
colon cancer cell lines have shown pterostilbene to be more potent than resveratrol in inhibiting
DNA synthesis and in decreasing the expression of inflammatory genes responsible for cancer
5

progression [39]. Although studies in other types of carcinomas show the potential efficacy of
resveratrol and pterostilbene, there has been barely any study to the best of our knowledge that
explores an anticancer mechanism that is specific for HPV-positive carcinoma (Table 1). Few
studies have utilized in vivo tumor models to determine the effectiveness of these two
compounds including pancreatic, colon and liver cancer [26,28,40–43]. Although several studies
delve into the pharmacokinetics and bioavailability of resveratrol and pterostilbene very little is
known about their in vivo potential in HPV positive cancer.
Table 1: Biological activity of resveratrol and pterostilbene on cervical cancer.
Compound

Study Type

Mechanism of

Reference

action
Resveratrol

In vitro

Apoptosis, Cell cycle

[44,45]

arrest
In vitro

Suppresses migration

[46]

and invasion
In vitro

Wnt, Notch, STAT3

[47]

In vitro

HIF-1α/VEGF

[48]

In silico

Interacts with p53

[49]

binding site of E6
Pterostilbene

In vitro

ER mediated
apoptosis

6

[50]

Table 2: Overview of clinical trials of resveratrol [40]
Cancer
type
Prostate
cancer

Study
conditions
14 patients,
phase 1clinical
trial

Length of
trial
2–31
months
(depending
on patient)

Resveratrol
dosage
500, 1000, 2000,
3000, or 4000 mg
of MPX. Every
500 mg MPX has
4.4 μg resveratrol

Biomarker
changes
Increase in
PSADT

Effect

Colorectal
cancer

9 patients
randomized,
placebocontrolled,
double blind,
phase 1 trial

14 days
prior to
surgery

5.0 g SRT501

augmentation in
cleaved
Caspase-3
(apoptosis)

Beneficial

Colorectal
cancer

20 patients

8 days
prior to
surgery

500 or 1000 mg

Decrease in
tumor cell
proliferation,
indicated by
reduction in Ki67 staining

Beneficial

Breast
cancer

39 patients,
randomized,
double-blind,
placebocontrolled
clinical trial

3 months

5 or 50 mg twice
daily

Decrease in
RASSF-1α
methylation

Beneficial

7

Beneficial

1.4 Role of high risk E6 in pathogenesis of Cervical cancer
Persistent infection with high risk HPV leads to cancer progression. The process involves
integration of the viral DNA into the host genome resulting in uncontrolled cellular proliferation.
As a result of this the virus loses its replicative property along with most of the viral
genes[51,52].

Illustration 2. Majors targets of E6 and their cellular consequences. Adapted from [52,53].

8

Viral oncogenes E6 and E7 are required for cellular transformation and malignancy. E6 is a vital
HPV oncoprotein essential for cervical cancer progression [53,54]. E6 binds to tumor suppressor
protein p53 and targets it for degradation by the ubiquitin proteasome pathway [51], thus causing
uncontrolled cell proliferation. Besides p53 E6 has several binding partners that target cellular
signaling pathways responsible for metastasis (Illustration 3). Some of the major targets of E6
are shown in the above illustration.

9

1.5 Scope of Work
In the current project, we first set out to compare the relative effectiveness of resveratrol and
pterostilbene on HeLa cells (HPV18), paying particular attention to their comparative IC50
values, changes in the levels of the HPV oncoprotein E6 and its target p53, as well as their
comparative pro-apoptotic and anti-migratory capacities (Chapter 2).
Further in Chapter 3 we set out to examine the efficacy of both these compounds in vivo. For this
purpose, we used a cervical cancer murine model injected with TC1 cells. These cells were
originally derived from mouse primary lung epithelial cells transformed with three oncogenes:
HPV16-E6, -E7 and c-Ha-Ras. TC1 tumor models have been widely used as a model for cervical
cancer and have been used to study in vivo effects of several therapeutic strategies [21,55,56].
Unlike resveratrol there are very few studies on the effects of pterostilbene in cervical cancer.
Furthermore, there is very little known about the anticancer effects of resveratrol and
pterostilbene in vivo in cervical cancer. In this study we comprehensively analyzed the efficacy
of these two polyphenols in HPV-oncogene positive tumors and explored the therapeutic
possibility of these natural compounds in vitro and in vivo. Our findings show for the first time
that these compounds can significantly reduce the size of HPV E6-oncogene positive TC1
tumors. Importantly, both compounds significantly reduced HPV E6, the oncoprotein driving
tumor formation. Only a short treatment cycle of 5 days was sufficient to see a significant
antitumor potential of resveratrol and pterostilbene. We propose that this antitumor efficacy is
dependent on two different mechanisms where resveratrol plays a vital role in arresting tumor
growth evident by a significant reduction of proliferating cell nuclear antigen (PCNA) and
pterostilbene largely causing cell death in tumors by activating apoptotic caspase-3.

10

CHAPTER 2

Resveratrol and Pterostilbene Exhibit Anticancer Properties
Involving the Downregulation of HPV Oncoprotein E6 in Cervical
Cancer Cells
Published work: Kaushiki Chatterjee et al. Nutrients 2018, 10(2),
243; https://doi.org/10.3390/nu10020243
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2.1 Abstract
Cervical cancer is one of the most common cancers in women living in developing countries.
Due to a lack of affordable effective therapy, research into alternative anticancer compounds
with low toxicity such as dietary polyphenols has continued. Our aim is to determine whether
two structurally similar plant polyphenols, resveratrol and pterostilbene, exhibit anticancer and
anti-HPV (Human papillomavirus) activity against cervical cancer cells. To determine anticancer
activity, extensive in vitro analyses were performed. Anti-HPV activity, through measuring E6
protein levels, subsequent downstream p53 effects, and caspase-3 activation, were studied to
understand a possible mechanism of action. Both polyphenols are effective agents in targeting
cervical cancer cells, having low IC50 values in the µM range. They decrease clonogenic
survival, reduce cell migration, arrest cells at the S-phase, and reduce the number of mitotic
cells. These findings were significant, with pterostilbene often being more effective than
resveratrol. Resveratrol and to a greater extent pterostilbene downregulates the HPV oncoprotein
E6, induces caspase-3 activation, and upregulates p53 protein levels. Results point to a
mechanism that may involve the downregulation of the HPV E6 oncoprotein, activation of
apoptotic pathways, and re-establishment of functional p53 protein, with pterostilbene showing
greater efficacy than resveratrol.

12

2.2 Materials and Methods

2.2.1 Cell Culture
Human cervical carcinoma HeLa cells were obtained from a commercial supplier (American
Type Culture Collection, Manassas, VA, USA) and were cultured in Dulbecco’s Modified Eagle
Medium: Nutrient Mixture F-12 (DMEM/F-12) (HyClone, GE Healthcare Life Sciences,
Manassas, VA, USA), supplemented with 10% fetal calf serum (HyClone, GE Healthcare Life
Sciences) and 0.1% Penicillin-Streptomycin Solution (HyClone). Cells were incubated in a 37
°C incubator with 5% CO2.
2.2.2 Determination of IC50 Using WST-1 Assay
Seven thousand cells were plated on 96-well plates and allowed to grow for 24 h. Resveratrol
(Acros, #430075000) or pterostilbene (TCI, #P1924) was serially diluted from 10–120 µM into
DMEM/F-12 plus 1× insulin-transferrin-selenium (ITS) supplement (Invitrogen). Cells were
treated with dilutions (in triplicate) for 24 h prior to performing a WST-1 (Water Soluble
Tetrazolium salt-1) cell viability assay. The WST assay involved aspiration of the medium after
treatment and rinsing three times with equal volumes of 1×Phosphate Buffered Saline (PBS),
followed by the addition of 80 µL of 10% WST-1 (Clontech, Mountain View, CA, USA) in
DMEM to each well. The plate was then incubated at 37 °C for 1 h and absorbance monitored at
440 nm using a plate reader. Results obtained were analyzed using GraphPad Prism 5 software to
determine the IC50 using a standardized method [57,58].
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2.2.3 Live Imaging
Images of untreated and treated (with resveratrol and pterostilbene) cells were taken every 10
min for 24 h to generate video files using a Zeiss Axio Observer Z1 microscope.
2.2.4 Clonogenic Assay
Two hundred thousand cells were plated on 6-well plates and allowed to grow for 24 h prior to
treatment with pterostilbene (50 µM) and resveratrol (50 µM) for 24 h. After 24 h, cells were
trypsinized to single cell suspensions. After cell counting, 150 viable cells from each treatment
set were plated in one well from a 6-well plate and allowed to grow in complete DMEM/F-12
medium for 15 days. After said period of time, cells were washed once with 1× PBS then fixed
and stained with 0.5% crystal violet in 6% glutaraldehyde for 30 min. The cells were briefly
rinsed with tap water and allowed to air dry. Images of each well was taken and colonies were
counted using ImageJ (NIH, Bethesda, Rockville, MD, USA). The plating efficiency and
survival factor was calculated as determined previously [59]
2.2.5 Scratch Assay
Twelve thousand cells were grown on 96-well plates until a confluent monolayer was formed. A
scratch was made with a sterile p200 tip in each well through the center of the culture. The debris
was washed off with serum-free media and a marking was made on the bottom of the plate to
take images at the same location. Cells were then treated with different concentrations (5 µM and
20 µM) of resveratrol or pterostilbene and brightfield images were taken after 48 h to allow
closure of the control scratch. The images were analyzed using ImageJ and the area of closure
was measured according to previous published methods [60].
14

2.2.6 Flow Cytometry
Two hundred and fifty thousand cells were cultured on 6-well plates and subsequently treated
with resveratrol or pterostilbene (5 µM, 10 µM, and 15 µM) for 18 h. Cells were trypsinized,
centrifuged, and washed with 0.1% Fetal Calf Serum (FCS) in 1× PBS solution and resuspended
in 70% ethanol at −20 °C, which was added dropwise while shaking the samples vigorously.
Fixed samples were kept at 4 °C for 1 h followed by washing twice in 1× PBS. Prior to flow
cytometry, cells were incubated with RNase (500 µg/mL) for 30 min at 37 °C and then stained
with propidium iodide (PI; 70 µM) for 30 mins. Cells were analyzed for DNA content by
measuring PI fluorescence using an Accuri C6 flow cytometer (BD).
2.2.7 Western Blot Analysis
Two hundred and fifty thousand cells were cultured on 6-well plates and subsequently treated
with resveratrol (10 µM, 50 µM) or pterostilbene (10 µM, 50 µM) for a period of 22 h.
Extraction of proteins from cultured cells was performed using M-PER Mammalian protein
extraction reagent (Thermo Fisher, Waltham, MA, USA) with protease and phosphatase
inhibitors. The total amount of protein in each well was quantified using the Lowry method. To
resolve the proteins, 25 μg of protein was subjected to sodium dodecyl sulfate-polyacrylamide
gel electrophoresis using a 10% acrylamide separating gel and then transferred to nitrocellulose
membrane for 1 h. The membrane was blocked at room temperature for 1 h with 5% nonfat dry
milk in Tris Tween Buffered Saline (TTBS). The nitrocellulose membrane was then incubated
overnight with a p53 antibody (sc-6243) followed by incubation at room temperature for 1 h with
anti-rabbit

IgG

conjugated

with

horseradish
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peroxidase.

SuperSignal

West

Pico

chemiluminescence substrate (Pierce) was used for detection following the manufacturer’s
instructions. The membranes were scanned using APHA INNOTECH Fluorchem SP imaging
system. Analysis of blots was done using ImageJ software.
2.2.8 Immunocytochemistry
Seven thousand HeLa cells were plated on 8-well chamber slides and allowed to grow for 48 h.
Cells were then treated with different concentrations of resveratrol (5–50 µM) or pterostilbene
(5–50 µM) for 22 h (for study of E6, p53 and cleaved caspase-3) and 18 h (for study of Phospho
histone H3). All treatments were performed in serum-free DMEM/F-12 containing 1%
supplement (ITS; insulin, transferrin, selenium; Gibco BRL, Grand Island, NY, USA). After
treatment, cells were fixed in 4% paraformaldehyde at room temperature, rinsed with 1× PBS,
and then permeabilized and blocked with 10% horse serum, 2% bovine serum albumin, and 0.5%
Triton X-100 in PBS for 1 h. The cells were then incubated overnight with primary antibodies in
blocking buffer. Subsequent to primary antibody treatment, the cells were washed and then
incubated with the respective Fluorescein isothiocyanate (FITC) conjugated secondary
antibodies for 3 h, followed by incubation with 4’,6-diamidino-2-phenylindole (DAPI) (10
µg/mL) and three washes with 1× PBS. The slides were then mounted with coverslips and cell
images were acquired using a Zeiss Axio Observer Z1 microscope and an AxioVision 4.6.3-AP1.
Images of different, randomly chosen fields were acquired with identical exposure times from
each well for quantification. ImageJ was used to measure the fluorescence intensity and cell
counting. The fluorescence intensities of E6 and P53 antibodies were normalized to DAPI
intensity (blue).
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Antibodies Used: E6 antibody (sc-460, Santa Cruz Biotechnology, Dallas, TX, USA), p53
antibody (sc-6243), cleaved caspase-3 antibody (D175, 9661, CST), Phospho Histone H3 (Ser
10) antibody (06–570, Millipore, Burlington, MA, USA).
2.2.9 Statistical Analysis
Statistical analyses were performed using Microsoft Excel® 2013 (Microsoft Corporation,
Redmond, WA, USA) and GraphPad Prism® 5 (GraphPad Software, Inc., La Jolla, CA, USA).
Means and standard deviations were calculated for each group. One-way ANOVA with Tukey
test was used to compare three or more datasets and determine the significance between the
groups. ANOVA is a test of variance and post hoc Tukey test used is for the determination of
significance between groups [61,62]. p < 0.05 was considered as significant.
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2.3 Results
2.3.1 Pterostilbene Is More Potent in Eliminating HPV+ HeLa Cells Compared to
Resveratrol
In order to study the comparative cytotoxicity of pterostilbene and resveratrol on HeLa tumor
cells, brightfield images (Figure 1A) and WST-1 cell viability assays (Figure 1B) were
performed 24 h post-treatment. The brightfield images taken after 24 h of treatment (Figure 1A)
showed that pterostilbene (40 µM) eliminates significantly more cells than resveratrol at the
same concentration. Live imaging of cells treated with 60 µM of the two compounds show
significantly more death and characteristic apoptotic blebbing in pterostilbene-treated cells when
compared to untreated or resveratrol-treated cells (Videos S1–S3). The WST-1 analysis revealed
that although both pterostilbene and resveratrol eliminated HeLa cells significantly and in a
dose-dependent manner, pterostilbene displayed a 1.97-fold lower IC50 when compared to
resveratrol (42.3 µM vs. 83.5 µM; p < 0.05; Figure 1B). Additionally, both compounds, at 50
µM, significantly inhibited the clonogenicity of post-treated cells in a 15-day clonogenic assay
(Figure 1C). Pterostilbene significantly reduced clonogenic survival by 87.5% compared to the
control (p < 0.05), while resveratrol inhibited it by 63% (p < 0.05) (Figure 1C). Moreover, the
difference between the survival percentages of the two treatment groups is significant (p < 0.05).
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Figure 1. Pterostilbene is more potent in eliminating HeLa cervical cancer cells as
compared to resveratrol: (A) Brightfield analysis of HeLa cells untreated (Ai) or treated for 24
h with 40 µM of resveratrol (Res; Aii) or 40 µM of pterostilbene (Pte; Aiii). Evidence of cell
elimination was only seen robustly in cells treated with pterostilbene at 40 µM. (B) Analysis of
IC50 values, generated by a Water Soluble Tetrazolium salt-1 (WST-1) assay after 24 h of
exposure to resveratrol or pterostilbene indicates that pterostilbene (IC50 = 42.3 µM) is a more
potent cytotoxic agent than resveratrol (IC50 = 83.5 µM; Bii). The graphs represent data from
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three independent experiments (mean ± S.E.M. (Standard error mean)). (C) Clonogenic assays
performed to compare the relative effect of the two polyphenols on the clonogenicity of HeLa
cells untreated (Ci) or treated with 50 µM of either resveratrol (Cii) or pterostilbene (Ciii).
Results are from 15-days post-treatment and indicate that pterostilbene is more efficient in
curbing the clonogenicity compared to resveratrol (Civ). Bar graph represents data from three
independent experiments (mean ± S.E.M.; * p < 0.05; Civ).
2.3.2 Inhibition of Cell Migration of HeLa Cells Treated with Pterostilbene and Resveratrol
To determine the comparative efficacy of resveratrol and pterostilbene in inhibiting HeLa cell
migration, two different sub-lethal concentrations of each compound were used in a 48-h scratch
assay (Figure 2). Based on the WST-1 results and brightfield images (unpublished), we found
that cells treated with a concentration below 25 µM showed no signs of cellular toxicity. To
avoid any cytotoxicity, we used lower concentrations of 5 µM and 20 µM. At sub-lethal
concentrations of 5 µM and 20 µM, both resveratrol and pterostilbene significantly inhibited
HeLa cell migration relative to untreated cells (p < 0.05; Figure 2). Pterostilbene was more
effective in inhibiting HeLa cell migration at 20 µM when compared to resveratrol; however, this
result was not significant and no differences were seen between the two compounds at 5 µM
(Figure 2). In an effort to analyze the effects of resveratrol and pterostilbene on cell migration,
we normalized the amount of migration into the scratch (wound) by untreated cells, to 100%.
Relative to this control, resveratrol-treated cells migrated only 71.2% (5 µM) and 63.7% (20
µM), while cells treated with pterostilbene migrated only 69.5% (5 µM) and 49.2% (20 µM)
(Figure 2).
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Figure 2. Resveratrol and pterostilbene inhibit cell migration: (A) HeLa cells were
monitored for cell migration into a scratched “wound”. Cells were either untreated or treated
with sub-lethal concentrations (5 µM and 20 µM) of resveratrol (Res) or pterostilbene (Pte). The
extent of migration into the scratched area was calculated after 48 h and revealed that both
resveratrol and pterostilbene significantly inhibit cell migration, although pterostilbene had
greater anti-migratory effect. (B) The graph represents data from triplicate sample experiments
normalized to the control (mean % migrated cells ± S.E.M.; * p < 0.05). Scale bar: 0.05 µm.
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2.3.3 Cell Cycle Arrest at S-Phase in HeLa Cells Treated with Low Concentrations of
Resveratrol and Pterostilbene
In order to compare the effect of sub-lethal doses of either resveratrol or pterostilbene on the cell
cycle of HeLa cells, treatment was carried out with three different concentrations (5 µM, 10 µM,
and 15 µM) of the two compounds for 18 h prior to flow cytometric analysis (Figure 3A). Flow
cytometry analysis showed that the cells treated with either compound exhibited a significant
decrease in the number of cells in the G2-M phase with respect to the control cells (p < 0.05)
(Figures 3A, B, Table 3), indicating an S-phase cell cycle arrest. This effect corresponded with
an increase in the number of cells arrested at the S-phase. Pterostilbene was significantly more
potent than resveratrol in inhibiting cell cycle progression, showing effects at concentrations as
low as 5 µM (p < 0.05) (Figures 3A, B, Table 3). At this concentration, pterostilbene had these
percentages of cells in each phase: G1 = 53.4 ± 1.4, S = 34 ± 1.4, G2 =12.5 ± 0.2, while
resveratrol had values of G1 = 64.8 ± 2.0, S = 16.3 ± 1.0, G2 = 18.3 ± 2.3. At a higher
concentration (15 µM) both compounds significantly inhibited cells from entering into G2-M by
arresting them in the S-phase, and difference between the extent of the arrest at this phase
induced by the two compounds was significant (p < 0.05) (Figures 3A, B, Table 3).
To confirm the cell cycle data, which indicated that both compounds are potent inhibitors of cells
entering into G2-M, we investigated the status of the M-phase mitotic marker phospho-histoneH3 by immunocytochemistry (Figures 3C, D). At concentrations of 10 µM, both compounds
significantly suppressed the amount of cells positive for the mitotic marker phospho-histone-H3,
when compared to the untreated cells control. Although resveratrol significantly suppressed the
abundance of phospho-histone-H3 (mitotic cells) at 5 µM, when compared to the control cells,
pterostilbene at this concentration was significantly more potent than resveratrol (Figure 3D).
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Relative to the control, which was set at 100%, cells treated with 5 µM pterostilbene exhibited
only 13.8% mitotic cells positive for the marker, which was significantly lower than the
resveratrol-treated sample at this concentration, which had 60% mitotic cells (Figure 3D; p <
0.05).

Figure 3. S-phase arrest in HeLa cells treated with low concentrations of resveratrol and
pterostilbene: (A) Flow-cytometric evaluation of HeLa cells untreated or treated with sub-lethal
doses of resveratrol (Res) and pterostilbene (Pte) for 18 h. Treated cells exhibited S-phase arrest
and a subsequent decrease in the number of cells in G2/M. Pterostilbene was a more potent
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compound than resveratrol, showing a capacity to arrest cells at the S-phase at concentrations as
low as 5 µM. (B) Graphical representation of the dose-dependent cell cycle effects induced by
resveratrol and pterostilbene at three different concentrations (5 µM, 10 µM, and 15 µM). (B)
The graph represents data from triplicate sample experiments normalized to the control (mean %
cells in each phase ± S.E.M.) (C) Immunofluorescent images of HeLa cells probed for the Mphase marker phospho-histone-H3 (serine10). HeLa cells were untreated or treated with 5 µM
and 10 µM of resveratrol or pterostilbene. Immunofluorescent images display a decrease of
histone-H3 in cells treated with both the compounds, the effects at 5 µM of pterostilbene is much
greater than those of resveratrol (at 5 µM). (D) Graphical representation of the percent of mitotic
cells calculated from immunofluorescent images reveal that resveratrol and to a greater extent
pterostilbene are effective in decreasing the number of mitotic HeLa cells. The graph represents
data from experiments obtained from triplicate samples normalized to the control (mean %
mitotic cells ± S.E.M.;* p < 0.05).
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Table 3. Table showing the percentage of cells in each phase of the cell cycle (% ± S.E.M.)
after treatment with different concentrations of resveratrol (Res) and pterostilbene (Pte).
G1 ± S.E.M. S± S.E.M.

G2 ± S.E.M.

Control

64.1±0.4

8.00±2.5

27.7±2.4

Res 5µM

64.8±2.0

16.3±1.0

18.3±2.3 ^

Pte 5µM

53.4±1.4 +

34.0±1.4 *

12.5±0.2 ^

26.5±0.2 *

14.4±1.0 ^

35.6±2.4 *

10.1±1.5 ^

Res 10µM 58.5±0.2
Pte 10µM

54.3±0.8 +

Res 15µM 61.3±1.9
Pte 15µM

52.3±2.0 +

27.1±0.8 *,# 11.5±1.2 ^
40.1±3.4 *,# 7.7±0.5 ^

+

p < 0.05 relative to G1 control, * p < 0.05 relative to S control, ^ p < 0.05 relative to G2 control,

#

p < 0.05 relative to each other.

2.3.4 Downregulation of Viral Oncoprotein E6 and Upregulation of Active-Caspase-3 in
HeLa Cells Treated with Pterostilbene and Resveratrol
In order to investigate how resveratrol and pterostilbene were affecting HeLa cell survival and
cell cycle progression, we treated cells with either of the two compounds at sub-lethal (10 µM)
and higher (50 µM) concentrations prior to analysis by immunostaining for E6, active caspase-3,
and p53 (Figures 4A–C). At 10 µM, both resveratrol and pterostilbene failed to significantly
affect levels of E6 and active caspase-3 levels relative to the control (Figures 4A, B). However,
at 50 µM both compounds significantly suppressed E6 levels and elevated cleaved caspase-3
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levels in treated cells relative to the untreated cells (Figures 3A–C). At this concentration (50
µM), pterostilbene was significantly more potent than resveratrol at suppressing E6 levels
(resveratrol = 0.77 ± 0.11: 23% decrease vs. pterostilbene = 0.57 ± 0.06: 43% decrease; p < 0.05)
and simultaneously elevating active caspase-3. It should be noted that we were unable to detect
any noticeable differences in the sub-cellular localization of E6 in treated cells (Figure 4A).

Figure 4. Downregulation of viral oncoprotein E6 and upregulation of active-caspase-3 in
HeLa cells treated with resveratrol or pterostilbene: (A) HeLa cells immunostained for E6
levels (green) and counterstained with the nuclear dye 4’,6-diamidino-2-phenylindole (DAPI)
(blue) after treatment with resveratrol (Res) and pterostilbene (Pte; 10 µM and 50 µM). Loss of
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E6 proteins are visually evident in cells treated with 50 µM of either resveratrol or pterostilbene.
(B) Cell image analysis of the E6 fluorescent data revealed a significant 43% decrease of E6
protein levels in HeLa cells treated with pterostilbene at 50 µM and a 23% decrease of E6 levels
in cells treated with resveratrol, both relative to the control. The graph represents data from
experiments obtained from three independent experiments normalized to the control (mean %
normalized to DAPI ± S.E.M.; * p < 0.05). (C) Immunofluorescent images probing for activecaspase-3 (green) shows a corresponding enhanced activation of this mediator of apoptosis by
both resveratrol and pterostilbene.
2.3.5 Upregulation of Tumor Suppressor Protein p53 in HeLa Cells Treated with
Pterostilbene and Resveratrol
Concomitant with E6 suppression, 50 µM pterostilbene treatment for 22 h caused an
upregulation of p53 in HeLa cells (Figures 5A, B). When compared to the control, pterostilbene
treatment elicited a 2-fold increase in p53 levels (staining normalized to DAPI; Figure 5B; p <
0.05). In comparison to the control, HeLa cells treated with 50 µM of resveratrol also caused an
upregulation of p53 (1.75-fold increase; Figures 5A, B; p < 0.05) at 22 h.
Total protein levels of p53 were also analyzed by Western blot in cells treated with either
resveratrol (10 µM and 50 µM) or pterostilbene (10 µM and 50 µM) for 22 h (Figures 5C, D).
Both compounds elevated p53 levels at 50 µM; however, significance was only noted in cells
treated with pterostilbene at this concentration (Figures 5C, D). Although cells treated with
pterostilbene at 10 µM tended to have elevated p53 protein levels relative to both the control
cells and cells treated with 10 µM of resveratrol, these differences were not significant based on
an ANOVA test (Figures 5C, D).
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Figure 5. Upregulation of the tumor suppressor protein p53 in HeLa cells treated with
resveratrol and pterostilbene: (A) Immunoflourescent images of p53 protein (green) untreated
or after treatment with 50 µM of either resveratrol (Res) or pterostilbene (Pte) for 22 h. Levels of
p53 are elevated in cells treated with either polyphenol. (B) Image analysis of p53
immunofluorescence indicates that pterostilbene treatment at 50 µM elicited a significant 2-fold
increase in p53, while resveratrol exposure at similar concentrations induced a significant 1.75
increase in p53. The graph represents data from experiments obtained from three independent
experiments normalized to the control (mean % normalized to DAPI ± S.E.M. * p < 0.05). (C)
Western blot analysis also revealed that the elevation of p53 protein levels is evident in HeLa
cells treated with 50 µM of resveratrol and pterostilbene; however, significant differences
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relative to the control were only reached with HeLa cells treated pterostilbene at 50 µM. (D) The
graph represents data from experiments obtained from three independent experiments normalized
to the control (mean % normalized to beta-actin ± S.E.M.; * p < 0.05).
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2.4 Discussion
In the current study, for the first time to our knowledge, we have compared the antitumor
potency of resveratrol and pterostilbene on E6+ cervical cancer cells in vitro. We demonstrated
that pterostilbene was significantly more potent than resveratrol in eliminating and in abrogating
the clonogenicity of these cervical cancer cells (Figure 1). To assess and study the effects of the
two compounds, we used a wide range of concentrations. Sub IC50 concentrations ranging from
5–20 µM were used to understand the action of these polyphenols at a low concentration. The
results show that at these concentrations the polyphenols can inhibit cell division and migration.
To further understand the cytotoxic mechanisms, it was imperative for us to look at supra IC 50
concentrations. We used 50 µM to understand the mechanism of action. The clonogenic assay
using this high concentration elucidates the long-term effect of these polyphenols on surviving
cells even after the removal of treatment. While sub-IC50 values of both compounds inhibited the
migration of E6+ cervical cancer cells, a higher sub-lethal concentration of resveratrol (20 µM)
was needed to exert any significant inhibitory effect. Nonetheless, pterostilbene caused a more
significant degree of inhibition to cell migration, attesting its superior antitumor potency (Figure
2). It is a notion held by cancer researchers that sub-IC50 concentrations of chemotherapeutic
drugs are ineffective in curtailing tumor malignancy. However, surprisingly, our data shows that
even at a low sub-lethal concentration (5 µM), pterostilbene is more effective than resveratrol as
an antiproliferative agent against cervical cancer cells by triggering cell cycle arrest at the Sphase (Figure 3). In addition to being effective at sub-IC50 concentrations, the supra-IC50
concentration of pterostilbene (50 µM) was also superior to resveratrol (at 50 µM) in suppressing
E6 while upregulating p53 and active-caspase-3 expression, thus causing a greater degree of
apoptosis-mediated cell elimination. This observed suppression of E6 and upregulation of p53 is
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of paramount importance because HPV infection and cancer progression in cervical cells relies
on the expression of the viral E6 oncoprotein which targets p53 for degradation by the
ubiquitination [63,64]. Thus, untreated cervical cancer cells continue to proliferate in the absence
of p53, unable to respond to cell stress and DNA damage. Our data indicates that resveratrol and
pterostilbene may restore an adequate p53 response and ultimately act as anticancer plant
compounds.
A comparative study between resveratrol and pterostilbene on colon cancer cells had shown
pterostilbene to be a more potent anticancer agent compared to resveratrol [32]. We hypothesized
that in cervical cancer cells we would see a similar effect with higher induction of apoptosis with
pterostilbene treatment. Our first approach to understand the comparative efficacy of resveratrol
and pterostilbene in HeLa cells was a cytotoxicity analysis, in addition to ascertaining the
inhibitory concentration (IC50) (Figure 1 and Video S1–S3). The results clearly indicated that
pterostilbene could eliminate HeLa cells much faster and at a significantly lower concentration
compared to resveratrol. We also further analyzed the cytotoxic potential of these polyphenols on
a second cell line, E6-positive murine TC1 cells, and found a similar trend in IC50 results for
resveratrol and pterostilbene, where pterostilbene is 2-fold more cytotoxic than resveratrol. Since
cancer cells are known to have enhanced clonogenecity [59,65], our study aimed to see the
survival capability of the cells treated with supra-IC50 concentrations of either resveratrol or
pterostilbene. Clonogenic studies show the long term-term effects of these polyphenols on
cervical cancer cells after treatment for 24 h and then allowing the surviving cells to grow in
normal growth medium for 15 days. Both compounds at supra-IC50 concentrations showed a
dramatic decrease in the clonogenic capacity of the surviving cells. These results suggest that
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resveratrol and pterostilbene may suppress new tumor growth often seen in high-grade metastatic
cervical cancer.
The migration of cancer cells is a very important factor responsible for the metastasizing of
cancers [66]. Inhibition of migration can play a major role in checking the progression of cancer
metastasis. Our study found that sub-cytotoxic doses of both compounds exhibit anti-migratory
roles. These findings are supported by previous studies, which have shown that resveratrol shows
anti-migratory activity by suppressing phorbol 12-myristate 13-acetate (PMA)-induced migration
in cervical cancer cells [67]. Studies in hepatocellular carcinoma indicate that pterostilbene
suppresses migration by downregulating MMP-9 expression [68]. These mechanisms might
possibly be responsible for inhibiting migration in HeLa cells and remain to be determined in
later studies.
Previous cell cycle arrest studies of resveratrol on HeLa cells showed that all the cells were
arrested at the S-phase and none remained in the G2/M-phase [45,69]. Pterostilbene shows cell
cycle arrest in several cancer studies [68]; however, to the best of our knowledge, no such study
on cervical cancer has been carried out. Our current study showed that pterostilbene shows
markedly better efficacy than resveratrol in arresting the cell cycle at the S-phase. To further
analyze the effects of the two compounds on cell cycle arrest, we looked at phospho-histone H3
as a marker for mitosis [70]. Our observations strengthen and confirm the results obtained from
flow cytometric analysis indicating that although both compounds are able to arrest mitosis,
pterostilbene has enhanced capacity to arrest cancer cell growth.
Although we initially used sub-lethal concentrations of the two compounds on HeLa cells to
decipher their antitumor mechanisms in the context of cell cycle arrest, it was imperative for us
to delineate the possible mechanism of elimination of HeLa cells by these compounds at higher
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concentrations. Pterostilbene is known to be effective on cervical cancer cells by Endoplasmic
reticulum (ER)-mediated stress development as well as by targeting the Nrf-2 pathway [50]. In
HPV+ cancer cells, the oncoprotein E6 degrades the tumor-suppressor protein p53 by targeting it
for proteasomal ubiquitination, which has been shown to augment the tumorigenic characteristics
of cancer cells [51,53]. In contrast, inhibition of E6 expression in the cancer cells would be
expected to allow p53 protein to trigger apoptosis and cell cycle arrest. Our findings support this
latter statement, with resveratrol and pterostilbene activating caspase-3 while simultaneously
downregulating E6 and upregulating p53. Our findings are partly supported by previous studies
indicating that resveratrol treatment on cervical cancer cell lines upregulates p53 [71]. Our
findings are the first to show a direct upregulation of p53 in HeLa cells by another polyphenol,
namely, pterostilbene. Importantly previous studies have shown that p53 and simultaneous
caspase-3 activation might be the key for triggering apoptosis in HeLa cells [72]. Our
experiments support this finding and ascertain that resveratrol and pterostilbene act as robust
agents capable of regulating the p53-dependent apoptotic pathway. The p53 protein, which is
usually very low in HeLa cells, was upregulated by resveratrol and pterostilbene, leading us to
hypothesize that reactivation of p53 in treated HeLa cells is a possible mechanism of action of
these compounds.
Cervical cancer is a major concern in developing countries due to lack of affordable prophylaxis
and treatment. As present modes of treatment like surgery, chemotherapy, or radiation involve
high systemic toxicity, there is an urgent need to find affordable alternative therapies. Diet-based
polyphenols like resveratrol and pterostilbene are therefore potential candidates for the effective
therapy of cervical cancer with significantly low toxicity. We found pterostilbene to be a more
potent anticancer agent than resveratrol in HeLa cells. This difference may be a function of
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pterostilbene being capable of upregulating p53 and downregulating E6 significantly more than
resveratrol. As pterostilbene is non-toxic to normal cells [37], it has the potential to be a robust,
cost-effective anti-E6+ tumor drug. Others have found that that pterostilbene possess greater
bioavailability and stability [73] than resveratrol in vivo (80% vs. 20%). Resveratrol has been
shown to be non-toxic to several cells lines like glial cells and neurons, even after a treatment
dose of 100 µM for 48 h [74]. Other studies on normal fibroblasts also state the non-toxicity of
resveratrol at our observed potent anticancer concentrations [75]. Additionally, pterostilbene
shows no toxicity at these concentrations in normal skin fibroblasts and myoblasts [76].
According to clinical studies, the safe dosage for resveratrol and pterostilbene is 5 g/day [29]and
250 mg/day [37], respectively. Our findings support the further evaluation of pterostilbene as a
possible therapy against cervical cancer.
Here, we show that pterostilbene potently suppresses HPV E6 expression (Figure 4) and
efficiently eliminates HPV+ cells in culture by p53-mediated apoptosis (Figures 1 and 5) while
suppressing cell proliferation (Figure 3) and migration (Figure 2). We find that pterostilbene is a
more promising agent against cervical cancer when compared to resveratrol. Based on such
properties, the use of pterostilbene presents a relatively economical but highly hopeful
therapeutic approach to treat HPV infections and cervical cancers. Our future studies will include
signaling studies using HPV+ murine tumor models to confirm these observations in vivo.
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CHAPTER 3

Resveratrol and Pterostilbene Inhibit E6 positive tumor growth in
vivo
Kaushiki Chatterjee et al. (submitted)
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3.1 Abstract
Human papilloma virus (HPV) induced-cervical cancer is one of the most frequent cancers in
women residing in underdeveloped countries. Natural compounds like polyphenols continue to
be of scientific interest as non-toxic effective alternative treatments. Our previous work showed
the efficacy of two polyphenols, resveratrol and pterostilbene on human HeLa cells. Here we
explored the in vitro anti-cancer activity and in vivo anti-tumor potential of these two structurally
similar compounds on HPV oncogene E6 and E7 positive murine TC1 cells. In vitro analysis
confirmed the cytotoxic potential of both resveratrol and pterostilbene compounds with each
having a low IC50 value and each showing the ability to downregulate viral oncogene E6. Further
our in vivo studies on TC1 tumors developing in mice indicated that treatment with either
resveratrol or pterostilbene can significantly inhibit tumor development. with both compounds
capable of downregulating E6 and VEGF tumor protein levels. Interestingly, the decrease in
tumor size in pterostilbene was associated with tumor cell apoptosis, as indicated by an
upregulation of activated caspase-3 whereas in resveratrol-treated mice it was accompanied by
arrest of cell cycle, as indicated by a downregulation of PCNA Thus, resveratrol and
pterostilbene can serve as potential antineoplastic agents for HPV E6+ tumors and hyperplasia,
.and may suppress tumor growth via two different mechanisms.
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3.2 Materials and Methods
3.2.1 Cell Culture. TC-1 mouse cells were procured from the lab of Dr. T.C. Wu at Johns
Hopkins University. TC-1 cells were derived from primary lung epithelial cells of C57BL/6 mice
after co-transformation with HPV16-E6, HPV16-E7 and c-Ha-Ras oncogenes [77]. The cells
were maintained in Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12)
(HyClone, GE Healthcare Life Sciences, Manassas, VA, USA), supplemented with 10% fetal
calf serum (HyClone, GE Healthcare Life Sciences) with 0.1% Penicillin-Streptomycin Solution
(HyClone). Cells were cultured in a humidified incubator at 37 °C incubator and 5% CO2.
3.2.2 Determination of IC50 Using WST-1 Assay. Four thousand TC-1 cells were plated on 96well plates and cultured for 24 hrs. Resveratrol (Acros, #430075000 ; > 99% purity tested by
HPLC) or pterostilbene (TCI, #P1924 : > 98% purity tested by HPLC) were serially diluted from
5–100 µM in DMEM/F-12 supplemented with 1 × insulin-transferrin-selenium (ITS; Invitrogen).
Treatment was carried out with the dilutions (in triplicate) for 72 hrs after which time a WST-1
(Water Soluble Tetrazolium salt-1; Clontech, Mountain View, CA, USA) cell viability assay was
performed. The medium was aspirated after treatment and rinsed three times with 1 × Phosphate
Buffered Saline (PBS). After rinsing, 80 µL of a 10% WST-1 fresh solution was prepared in
DMEM and subsequently added to each well. The plate was then incubated for 1 hr at 37°C to
get a color reaction. The absorbance was recorded at 440 nm using a 96-well spectrophotometer.
The results were then analyzed using GraphPad Prism 7 software to obtain the IC 50 using a
standardized method[78].
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3.2.3 Immunocytochemistry. TC-1 cells were cultured on 8-well chamber slides for 48 hrs prior
to immunocytochemistry. The cells were then untreated (control) or treated with resveratrol (30
µM) or pterostilbene (30 µM) for 48 hrs prior to immunocytochemical detection of E6. The
dilutions of resveratrol and pterostilbene were done in serum-free DMEM/F-12 containing 1%
supplement (ITS; insulin, transferrin, selenium; Gibco BRL, Grand Island, NY, USA). After the
completion of the treatment period the cells were fixed in 4% paraformaldehyde. Further
processing of the fixed cells and probing with E6 antibody (sc-460; Santa Cruz Biotechnology)
was carried out as described previously [78].
3.2.4 TC-1 mouse model generation and treatment. 50,000 TC-1 cells harvested from actively
growing cultures were injected subcutaneously in the nape of the neck of female C57BL/6 mice,
which were approximately 2-3 months old. This tumor model has been standardized and used in
previous studies [21,79]. Once palpable tumors were formed (in approximately 15-20 days)
treatment cycles was initiated. Treatment involved the mice being randomly divided into three
groups, control, resveratrol and pterostilbene - with each group containing 4 mice. Tumors were
marked into four quadrants and 10 µl of the 1 mM resveratrol or 1 mM pterostilbene was
injected into each quadrant intralesionally for 5 consecutive days. The control group of mice
were subjected to 1 x PBS injections also for 5 consecutive days. After the completion of the
treatment cycle the mice were sacrificed and the tumors were excised. Tumor volumes for the
excised tumors were measured using a caliper and volumes were calculated as previously
mentioned [21]. Tumors were then fixed and processed for immunohistochemistry. All mouse
experiments were performed according to NIH guidelines for animal use and approved by the
Institutional Animal Care Committee (IACUC) of the College of Staten Island (CUNY)
(approval # 11−008).
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3.2.5 Immunohistochemistry. Tumor sections that were taken from the approximate center of
the tumor were randomly selected from each group for immunohistochemical analysis. The
sections were first subjected to antigen-retrieval using formamide: 2 × SSC at 55°C for 2 hr
followed by two PBS washes. The sections were then blocked with 3% goat serum or 10% rabbit
serum for 2 hrs and then treated overnight with primary antibodies: anti-E6 antibody (sc-460;
Santa Cruz Biotechnology) or VEGF (P-20; Santa Cruz Biotechnology) or PCNA (#2586 Cell
Signaling Technology) or Cleaved Caspase-3 (Asp 175) (#9661; Cell Signaling Technology).
The antibodies were diluted in 2% goat serum or 2% rabbit serum and 0.1% Triton X in PBS.
The sections were washed with PBS after the primary treatment and then probed with the
secondary antibody. For E6 primary antibody the secondary antibody used was Alexa Fluor 488
goat anti-mouse (Invitrogen) and for VEGF primary the secondary antibody used was Alexa
Fluor 488 rabbit anti-goat (Invitrogen). Sections were also stained only with the secondary
antibodies as a negative control for the experimental setup. After overnight incubation with
secondary antibody at 4 °C the sections were washed and stained with nuclear stain DAPI
(10 µg/ml) for 15 min at room temperature. The sections were then mounted on a slide with Gold
anti-fade mounting fluid. Confocal Images of the immunostained sections were taken using a
Leica SP2 microscope from multiple randomly chosen fields of multiple sections.
3.2.6 Image quantification and data analysis. All images taken were quantified using ImageJ
software. The empirical data obtained from all experiments were analyzed using GraphPad Prism
7 software.
3.2.7 Statistical analysis. Statistical analyses were performed using GraphPad Prism® 7
(GraphPad Software, Inc., La Jolla, CA, USA). The mean and standard error mean was obtained
for the groups. One-way ANOVA with Tukey test was used to compare the data sets and
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determine the significance as performed in previous publication[78]. p < 0.05 was considered as
significant.

3.3 Results
3.3.1 Resveratrol and Pterostilbene are cytotoxic to TC1 cells. Based on the findings of our
previous studies on HeLa cells showing the cytotoxic potential of resveratrol and pterostilbene
[78], we wanted to determine their anticancer efficacy on HPV-E6-positive mouse TC1 cells.
Brightfield images were taken after 48 hrs of treatment with different concentrations of
resveratrol or pterostilbene to see their cytotoxic potential relative to untreated control cells
(Figure 6A). A qualitative analysis of the images indicates that compared to control untreated
cells, both resveratrol and pterostilbene show significant cytotoxicity, with pterostilbene showing
more cell death and cytoplasmic blebbing than resveratrol after 48hrs. These comparative effects
are visible even at low concentrations of 10 µM and apoptotic cell numbers increased in a dose
dependent manner for both treatment groups. Analytically we ascertained the IC 50 concentrations
of these two polyphenols by performing a WST-1 assay for cell viability (Figure 6B). The results
showed the IC50 of resveratrol to be 34.46 µM (Figure 6Bi) while that of pterostilbene was
greater than 2-fold less at 15.61 µM (Figure 6Bii). These IC50 values were significantly different
from each other (p < 0.0001) and confirm the superior cytotoxicity of pterostilbene over
resveratrol in vitro on TC1 cells (Figure 6B).
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Figure 6. Resveratrol and pterostilbene are cytotoxic to TC1 cells. (A) Brightfield analysis of
TC1 cells untreated (Control) or treated with 10 µM ,20 µM and 30 µM of resveratrol (Res) or
pterostilbene (Pte). (B) IC50 values generated using a water soluble tetrazolium salt-1 (WST-1)
assay after 72 hrs of exposure to resveratrol or pterostilbene shows that pterostilbene is more
cytotoxic than resveratrol (IC50 = 15.61 µM vs. IC50 = 34.46 µM; p <0.0001, n =3). (Biii) Bar
graph represents comparative data showing the difference in viable cells treated with resveratrol
or pterostilbene at 20 µM or 40 µM (mean ± S.E.M.; * p < 0.05, n = 3)
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3.3.2 E6 oncoprotein gets downregulated by resveratrol and pterostilbene in vitro. To
investigate whether the expression of HPV viral oncoprotein E6 was attenuated by either
polyphenol treatments, we used immunocytochemical techniques to probe for protein levels in
TC1 cells. Using the results from the brightfield images and the IC50 values we selected a supra
IC50 concentration at 48 hrs for treatments (30 µM). Immunocytochemical analysis indicated that
cells treated for 48 hrs with pterostilbene but not resveratrol had significantly lower E6 levels
when compared to control (Figure 7A, B; p < 0.0001). Although E6 expression levels in
resveratrol treated cells were downregulated by 12% compared to control this down regulation
was not statistically significant (Figure 7B; p=0.1838). The downregulation of E6 levels by
pterostilbene was also significantly different than resveratrol (p < 0.0002). Therefore, our results
show that in vitro pterostilbene is more potent in downregulating the essential oncoprotein E6 in
TC1 cells as compared to resveratrol treatment.
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Figure 7. Viral oncoprotein E6 gets downregulated in TC1 cells treated with resveratrol or
pterostilbene. (A) TC1 cells immunostained and probed for E6 oncoprotein (green) and
counterstained with nuclear stain DAPI (blue). Cells treated for 48 hrs with resveratrol (30 µM)
or pterostilbene (30µM) shows pterostilbene has a more significant downregulation of E6 protein
expression as compared to resveratrol and control. B) Bar graph indicates the percent decrease in
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E6 expression in treated TC1 cells as compared to control untreated TC1 cells. The graphs
represent data from three independent experiments (mean ± S.E.M.; * p < 0.05; B).

3.3.3 Reduction of tumor size in mouse model by resveratrol and pterostilbene. To find out
the potency of these two polyphenols in vivo we generated mouse tumors by implanting TC1
cells subcutaneously in syngeneic C57Bl/6 female mice. After palpable tumors were formed, we
treated the mice intralesionally with resveratrol and pterostilbene for 5 consecutive days. After
completion of the treatment cycle the tumors were excised, and the volume of the tumors were
measured using a caliper and volumes were calculated as mentioned previously [21] (Figure
8A).The tumor size was drastically lower than the untreated tumors for both the treatment
groups. The radical decrease of tumor load clearly shows the high anticancer and tumor
inhibitory potential of resveratrol and pterostilbene (Figure 8B). Tumor volumes were measured
and graphed showing that the tumor size decreased by 83.6% in resveratrol treated groups and
72% in pterostilbene treated groups (Figure 8C). The reduction of size for both treatment groups
is significant compared to control (p<0.0001).
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Figure 8. Inhibition of tumor growth in E6+ tumor bearing mouse. A) Schematic
representation of mouse TC1 tumor in vivo tumor generation and subsequent treatment cycle.
TC1 cells were injected subcutaneously in 12 mice followed by daily palpations. After 15 to 20
days, when the tumors became apparent mice were divided into three groups of 4 and treated
intralesionally with either PBS (control), resveratrol or pterostilbene for 5 consecutive days.
After 5 days the mice were sacrificed, and the tumor excised. B) Tumors excised from the 3
groups, displayed for imaging and measured for size. In both treatment group tumors show
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marked decrease in tumor size compared to control. C) Bar graph shows percent reduction in
tumor size in mice treated with resveratrol or pterostilbene in comparison to control tumor.
Tumor size reduction is significant in the treated groups. The graphs represent data from 4 mice
from each group (mean ± S.E.M.; * p < 0.05; C).

3.3.4 Reduction of E6 oncoprotein level in vivo by resveratrol and pterostilbene. To
determine if E6 is downregulated in the resveratrol and pterostilbene treated tumors we used
immunohistochemistry. E6 protein levels can be seen to be very high in control untreated tumor
sections (Figure 9A). However, the treated groups show much lower expression of E6 indicating
that both the polyphenols can target E6 for downregulation. In control tumors almost all the cells
are E6 positive with high level of expression. In resveratrol and pterostilbene treatment not only
are the number of E6 positive cells reduced but also the level of protein expression in these cells
is lower. The fluorescence intensities of the tumor sections were compared and graphed (Figure
9B). Resveratrol has an intensity of 20.6±5.1 (79% decrease vs. control) and pterostilbene has a
total intensity of 10.5±2.2 (89% decrease vs. control). These finding indicate that both
polyphenols can significantly downregulate the expression of E6 in murine tumors compared to
untreated tumors (p<0.0001) and corroborate the tumor volume reduction data.
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Figure 9. E6 expression is reduced in mouse tumors. A) Tumor sections immunostained with
E6 antibody shows decreased E6 protein (green) in mice treated with resveratrol or pterostilbene
when compared to control untreated tumors. Sections were counterstained with DAPI (blue).
Scale bar: 47.62 µm. B) Graph indicates the significant reduction of E6 expression levels in
resveratrol or pterostilbene treated tumors in comparison to control tumors sections (mean ±
S.E.M.; * p < 0.05; C).
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3.3.5 Downregulation of PCNA protein in vivo by resveratrol and upregulation of cleaved
caspase 3 by pterostilbene. To understand the underlying mechanism(s) of tumor inhibition by
these two polyphenols we analyzed by immunohistochemistry the apoptotic marker, activated
caspase-3 (Figure 10 A, B), and the proliferation marker, PCNA (Figure 11 A, B). These results
indicated that tumors treated with pterostilbene have a significant amount of activated caspase-3
protein compared to resveratrol and control tumors (Figure 10A). The percentage of apoptotic
cells represented graphically in Figure 10B indicates that in vivo resveratrol treatment does not
appear to activate the process of caspase-3-mediated apoptosis whereas pterostilbene treatment
significantly increased this pathway (16.34% vs. 2.72%; p<0.0001). The difference in activation
of caspase-3 by pterostilbene is also significantly greater than tumors treated with resveratrol (p
< 0.0001). In contrast resveratrol treated tumors showed a significantly lower expression of
PCNA compared to untreated and pterostilbene treated tumors (Figure 11A). The percentage of
cells expressing PCNA reduced by 75.5% in resveratrol treated tumors compared to control
(25.26±10.5 vs 100±5.6; p < 0.0004). Moreover, the downregulation of PCNA positive cells by
resveratrol is significantly different than tumors treated with pterostilbene (p < 0.0006). Taken
together these results show that resveratrol targets a downregulation of proliferation (Figure 11A,
B) whereas pterostilbene activates apoptosis in TC1 tumors (Figure 10A, B), with both
polyphenols providing a substantial decrease in tumor growth compared to control untreated
tumors.
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Figure 10. Upregulation of activated caspase 3 in mouse tumors. A) Tumor sections
immunostained with cleaved caspase 3 antibody shows elevated protein levels (green) in mice
treated with pterostilbene when compared to control untreated tumors. Resveratrol treated tumors
did not show any significant change in caspase 3 expression. Sections were counterstained with
DAPI (blue). Scale bar: 47.62 µm. B) Graph indicates the significant increase of Cleaved caspase
3 expression levels in pterostilbene treated tumors in comparison to control tumors sections
(mean ± S.E.M.; * p < 0.0001).
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Figure 11. Downregulation of PCNA expression in mouse tumors. A) Tumor sections
immunostained with PCNA protein (green) and counterstained with nuclear stain DAPI (blue).
Resveratrol treated tumors display a significant decrease in PCNA expression compared to
control sections. Pterostilbene treated tumors show similar PCNA levels as control. Scale bar:
47.62 µm. B) Quantitative analysis of PCNA expression shows a significant change in
resveratrol treated tumor sections (mean ± S.E.M.; * p < 0.0004; B). The two treatment groups
show significant differences in PCNA expression (p< 0.0006).
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3.3.6 Downregulation of VEGF protein in vivo by resveratrol and pterostilbene. E6 is
known to upregulate VEGF expression in HPV positive tumor cells [80] therefore, we analyzed
VEGF expression as a biomarker for E6 loss of function. Immunohistochemical analyses of
tumor tissue showed that VEGF expression is lowered by the treatment of either resveratrol or
pterostilbene (Figure 12A). Control tumor sections show a high expression of VEGF whereas
treatment with either resveratrol or pterostilbene lowered the protein levels. The reduction is seen
ubiquitously throughout the tumor sections in both the treated groups. The graph ascertains the
level of downregulation with resveratrol showing a reduction to 60.5% (60.57±3.13) and
pterostilbene to 66.8% (66.88±2.8) compared to control (100%) (Figure 12B). Both treatments
were able to significantly downregulate the expression of VEGF protein(p<0.0001).

51

Figure 12. Downregulation of VEGF expression in mouse tumors. A) Tumor sections
immunostained with VEGF protein (green) and counterstained with nuclear stain DAPI (blue).
Both resveratrol and pterostilbene treated tumors display a significant decrease in VEGF
expression compared to control sections. Scale bar: 47.62 µm. B) Quantitative analysis of VEGF
expression shows a significant change in treated tumor sections (mean ± S.E.M.; * p < 0.05; B).
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3.4 Discussion
In the current study we have elucidated for the first time the efficacy of stilbene compounds,
resveratrol and pterostilbene using an in vivo murine E6 positive tumor model. We first
demonstrated that in vitro pterostilbene shows a higher efficacy in eliminating TC1 E6-positive
cells, when compared to resveratrol (Figure 6). It is important to note that both compounds show
significant cytotoxicity when compared to untreated cells. Analytically, we determined that the
IC50 of pterostilbene was approximately 2-fold less when compared to resveratrol (Figure 6).
Further in vitro analysis revealed that pterostilbene targeted significant downregulation of the
HPV oncoprotein E6 (Figure 7), which drives these cells to form tumors in vivo. In comparison,
cells treated with resveratrol exhibited less E6 compared to untreated controls, but the results
were not statistically significant (Figure 7). Both the compounds were unable to elicit significant
changes in E7 levels in TC1 cells (Figure 13). The in vitro results show that these polyphenols
are cytotoxic to TC1 cells and both show promise in downregulating the oncoprotein E6 with
pterostilbene showing superior antitumor potential (Figure 6,7).
To evaluate the efficacy of these polyphenols in vivo we established TC1 tumors in C57BL/6
mice and subjected them to intralesional treatment with 5 daily injections of 10 ul of resveratrol
(1mM) or pterostilbene (1mM). At the end of the treatment cycle, tumors treated with either
resveratrol or pterostilbene were significantly smaller than those treated with 1 x PBS alone
(Figure 8). Resveratrol was able to reduce tumor size an average of 83 % while pterostilbene
reduced tumor size an average of 72 %, when compared to control. The difference in tumor
reduction between resveratrol and pterostilbene was not significant, which was unexpected given
the potency of pterostilbene to more efficiently reduce E6 in vitro. When we assessed the E6
protein levels by using immunohistochemistry on tumor tissue we found resveratrol and
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pterostilbene both significantly inhibit E6 expression when compared to PBS (control) treated
tumors, although resveratrol downregulated E6 to a lesser extent (Figure 9). Upon further
examination we were able to demonstrate that pterostilbene causes significant apoptosis in the
tumors whereas resveratrol plays a major role in arresting the growth of these tumors. Therefore,
this study shows for the first time, to the best of our knowledge that resveratrol and pterostilbene
can exhibit antitumor activity and reduce tumor load by two distinct mechanisms; resveratrol
through cell cycle arrest (down regulation of PCNA) and pterostilbene through apoptosis
(upregulation of caspase-3; Figure 10,11). Of the multiple possible downstream targets of E6,
VEGF overexpression is of supreme importance in cervical cancer biology [80]. Delving deeper
into the possible targets of these polyphenols we found that angiogenic protein VEGF is
significantly reduced by both these natural compounds (Figure 12). Thus, our findings show the
potency of resveratrol and pterostilbene on TC1 tumors by downregulating the oncoprotein E6,
which drives TC1 tumor growth. The robust capability of these natural plant compounds to arrest
and eliminate E6 positive tumor cells is promising for those researchers looking for alternative
therapies to cervical cancer or for a better understanding of E6 oncogene activity.
We first confirmed the cytotoxic potential of resveratrol and pterostilbene on TC1 cells in vitro.
Our results showed that pterostilbene is 2-fold more potent than resveratrol in eliminating TC1
cells (Figure6). This corroborated our previous findings on HeLa cells where we had seen a
similar pattern of IC50 with pterostilbene showing superior efficacy than resveratrol [78]. HPV
E6 oncoprotein is known to play an essential role in cervical carcinogenesis. Both E6 and E7
protein expression is required for continuous cell proliferation and metastasis. Studies have
confirmed that eliminating E6 oncoprotein pushes the cells towards cell growth arrest and
apoptosis [53,54]. Our previous study on HeLa cells showed that although both resveratrol and
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pterostilbene downregulate E6 expression, pterostilbene has higher inhibitory efficacy compared
to resveratrol [78]. In the current study we see a similar trend in E6 level suppression, with
pterostilbene treatment showing greater suppression of E6 protein levels than resveratrol
treatment (Figure 7). This increased efficacy of pterostilbene may be attributed to its structural
stability. The methoxy group in pterostilbene makes it more lipophilic and more bioavailable
than resveratrol which has a single hydroxyl group [38,73]. Pharmacokinetic studies have also
established the superior bioavailability of pterostilbene over resveratrol [73,81].
Previous studies by our team on the human cervical cancer cell line HeLa also showed the
cytotoxic potential and anticancer properties of these two polyphenols in vitro [78]. Here our aim
was to further validate these compounds as promising cervical cancer therapies and to more
importantly evaluate their anticancer potential using in vivo model of cervical cancer. To achieve
this goal, we used TC1 cells which are E6, E7 and c-Ha-Ras positive transformed mouse
epithelial cells. Due to a lack of cervical cancer mouse models, TC1 cells have been widely used
for creating E6-positive mouse tumors to test vaccines and other therapies [21,77,82]. Several
studies have utilized this model to understand the role the immune system and microenvironment
in HPV cancers and also study immunotherapeutic strategies [79,83,84]. Combinatorial studies
using natural compounds including resveratrol has been successfully tested on TC1 tumor
models [21,79]. However, there has been no study that has investigated the potential of
resveratrol and pterostilbene individually on a cervical cancer model.
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Figure 13. E7 expression in TC1 cells. A) TC1 immunostained with E7 protein (green) and
counterstained with nuclear stain DAPI (blue). Both resveratrol and pterostilbene treated cells
were unable to cause significant change in protein expression.

Several in vivo studies show that resveratrol has anticancer properties against breast cancer,
colorectal cancer and liver cancer in rat and mouse tumor models [28]. In humans, resveratrol is
well tolerated with low toxicity and multiple clinical trials have proven the beneficial effects of
this polyphenol on colorectal cancer and breast cancer to name a few [40]. Pterostilbene has
gained a lot of attention in recent years as a more potent bioavailable analog of resveratrol.
Clinical trials also indicate the low toxicity of pterostilbene up to 250 mg/day dosage [37].
Pterostilbene has shown potential in abrogating several cancers like breast and colon cancer in
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animal models [36]. Although preclinical studies show the potency of pterostilbene on several
types of cancers , there is a lack of large scale clinical studies [38]. The in vivo efficacy of these
two polyphenols on cervical cancer has also not been substantially explored. Our studies bring to
light their strong potential to reduce tumor growth in a mouse cervical cancer model. The results
show support toward clinical trials investigating resveratrol and pterostilbene in late stage
cervical cancer, when local resection of tumor is not effective or as a possible preventative
treatment to those individuals with chronic HPV cervical infection in the absence of tumor.
Suppression of apoptosis and uncontrolled proliferation are major steps essential for progression
and metastasis of cancer [54]. Resveratrol and pterostilbene are known to have proapoptotic,
chemo preventative and anticancer properties [34]. Keeping in mind the extensive reduction of
tumor growth seen in vivo we wanted to explore if resveratrol and pterostilbene trigger the
apoptotic pathway. Several studies have shown that both these polyphenols can induce apoptosis
in several cancer cell lines including cervical cancer [32,44,78,85]. Our result showed that
pterostilbene but not resveratrol is able to induce considerable apoptotic cell death in TC1 tumor
cells in vivo. The upregulation of pro-apoptotic activated caspase-3 by pterostilbene was
significantly higher than untreated tumors whereas, resveratrol showed barely any change
(Figure 10). The difference in caspase-3 activation between the two treatments was statistically
significant and it was surprising to us given resveratrol’s potency to induce cell death in our in
vitro studies. We then further analyzed the growth inhibitory effects of these two polyphenols in
tumor tissue by performing immunohistochemistry for PCNA. PCNA is known to be highly up
regulated in HPV positive cancers [86] and is known to play a major role in cancer neoplasia
[87]. Our results showed that resveratrol, but not pterostilbene, can drastically downregulate
PCNA expression in TC1 tumors. The untreated and pterostilbene treated tumors had similar
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PCNA expression patterns (Figure 11). Our findings elucidate that resveratrol and pterostilbene
reduce tumor size by possibly two different mechanisms, resveratrol by downregulating growth
and pterostilbene by upregulating death of tumor cells. It is known that pterostilbene is more
bioavailable than resveratrol in vivo [73,88]. In our studies on HeLa cells we had seen that
resveratrol can cause cell cycle arrest at a sub IC50 concentration [78]. We think that possibly
pterostilbene being more bioavailable is absorbed more in the tumor resulting in a higher internal
concentration compared to resveratrol which being less bioavailable results in a lower intratumoral concentration. Based on our previous study and current results we hypothesize that
resveratrol with a lower tumor concentration induces cell cycle arrest whereas pterostilbene
remains at a high concentration within the cell and thus triggering apoptosis.
HPV E6 is an oncoprotein which has several important targets that can affect cellular pathways
leading to oncogenesis [52]. Studies have shown that HPV E6 is associated with activating the
promoter for VEGF gene in cervical cancers [80]. VEGF is known to induce angiogenesis, tumor
cell proliferation and plays a vital role in cervical neoplastic progression [89]. Current therapies
for recurrent cervical neoplasia include the usage of bevacizumab (Avastin) which is an antiVEGF antibody [48]. Unfortunately treatment with Avastin is associated with several serious
side effects including hemorrhaging [48]. Previous studies have shown that resveratrol can
inhibit angiogenesis by targeting HIF-1α and VEGF in cervical cancers cells [48]. Pterostilbene
has also shown anti-angiogenic properties in skin and lung cancers [36]. However there have
been no studies evaluating pterostilbene’s efficacy in cervical cancer. In the current study we
found that both resveratrol and pterostilbene can downregulate VEGF expression and therefore
should be further evaluated as alternative or complement to current anti-angiogenic cervical
cancer therapies. Both treatment groups can downregulate VEGF expression equally (Figure
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12). As VEGF is an important target for therapy our findings establish the therapeutic potential
of resveratrol and pterostilbene in HPV positive cancers.
Cervical cancer remains prevalent in many countries where anti-HPV vaccines and preventative
preneoplastic assessments are not routinely provided. Here we provide strong evidence that the
natural compounds pterostilbene and resveratrol are effective in drastically shrinking a cervical
cancer tumor model in vivo when injected directly into the tumor. Further studies, analyzing our
tumor model treated with systemic injections of these compounds is the next appropriate step.
Given these compounds are well tolerated in humans, they may provide clinicians with a viable
therapy in the treatment of cervical cancer, especially when current therapies are not available
because of the high cost to the patient.
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CHAPTER 4

Conclusion and future directions
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4.1 Concluding Remarks
This study elucidates the anti-cancer properties of two structurally similar natural compounds,
resveratrol and pterostilbene in vitro and in vivo. Our studies on HeLa cells showed the superior
anticancer properties of pterostilbene over resveratrol. Both the polyphenols were able to cause
apoptosis at higher concentration and arrest proliferation at lower concentrations. We were able
to link the cellular toxicity of these compounds to be a function of E6 downregulation. The
extent of E6 downregulation corresponds to a concurrent upregulation of p53 expression which
leads to apoptotic cell death. The polyphenols arrested cell cycle, stopped cell migration and
reduced the clonogenic potential of the cancer cells. In all the studies on HeLa cells it was clearly
seen that pterostilbene had a higher potency than resveratrol to annihilate and arrest metastasis
and invasion.
To further investigate if these effects can be translated in vivo, we used TC1 implanted mice.
After the completion of the treatment cycle a drastic reduction in tumor size was seen in both the
treatment groups. Unlike the in vitro results which showed pterostilbene to be more potent, the in
vivo tumor studies showed there is no difference in their tumor inhibiting potential. When we
delved in deeper to understand the targets, we found E6 to be downregulated along with
angiogenic marker VEGF. Surprisingly, the two compounds inhibited the tumor growth by
possibly two different pathways. Pterostilbene treatment caused apoptosis in the tumors whereas
resveratrol treatment inhibited cell proliferation. This shows the tumoricidal potential of
pterostilbene versus the tumoristatic potential of resveratrol. The potential of resveratrol to
inhibit tumor progression provides proof of its efficacy and negates the possibility of it being a
pan assay interfering compound.
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The ability of resveratrol and pterostilbene to be cytotoxic to cervical cancer cells and tumors
may be via a p53 dependent or independent pathway. E6 being the major target of both these
compounds several effector pathways may be disrupted. Our study on HeLa cells indicated that
both these polyphenols may be causing apoptosis by a p53 mediated pathway. A stabilization of
p53 or an upregulation of p53 may have been induced by downregulation of oncoprotein E6.
Recent study using resveratrol on HeLa cells have shown similar results with elevated p53
leading to apotosis [90]. E6 is able to effect several proteins besides p53 that can lead to
apoptosis. In our study we have looked at the effect of resveratrol and pterostilbene on some of
the major hallmarks of cancer (Illustration 3). As resveratrol and pterostilbene can downregulate
E6 in both HPV 16 and HPV18 strains we presume that there are multiple pathways that are
being affected which leads to tumor growth reduction and inhibition. Both the polyphenols are
pleiotropic and are effective against different types of tumors concurrently being non toxic to
normal cells. Further studies are required to fully understand the underlying meachanism of
action of the two polyphenols.
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Illustration 3. Hallmarks of cancer targeted by E6. [91]
The robust antitumor action of resveratrol and pterostilbene in vivo gives a valuable new
information in the field of natural compounds in cervical cancer and can be used as a potential
therapeutic drug in treatment of metastatic cancer.
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4.2 Future Directions:
This work raises some important questions.
Q1. What would be the outcome of a long-term treatment?
Our in vivo study was only limited to 5 consecutive days. Question remains if the long-term
treatment can eliminate the tumors completely and result in disease free survival.
Q2. Will removing the treatment result in tumors coming back and will the two compounds
show a difference?
Our study showed that resveratrol stops tumor proliferation whereas pterostilbene causes tumor
cell death. It is possible that on removal of the treatment the tumors treated with resveratrol can
bounce back and start dividing. Is the pterostilbene treatment more potent as it is irreversible cell
death?
Q3. What are the other targets of these compounds?
There are several other pathways that regulate the process of metastasis. Further analysis of
differential and altered protein expression needs to be done to understand the mechanism of
action of resveratrol and pterostilbene.
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